Group 1: Core Insights - Rongchang Biologics (09995.HK) announced that its innovative drug Taitasip (brand name: Tai Ai®) for treating primary Sjögren's syndrome has met the primary endpoint in a Phase III clinical trial in China [1] - Taitasip is the first BLyS/APRIL dual-target fusion protein drug to complete Phase III research in the field of Sjögren's syndrome globally [1] - The clinical trial was a multi-center, randomized, double-blind, placebo-controlled study aimed at evaluating the efficacy and safety of Taitasip, with the primary endpoint being the change in ESSDAI score at week 24 compared to baseline [1] Group 2: Disease Background and Drug Mechanism - Sjögren's syndrome is a chronic inflammatory autoimmune disease characterized by lymphocytic infiltration and damage to exocrine glands, leading to persistent dry mouth and dry eyes, and can affect multiple organ systems [2] - The prevalence of Sjögren's syndrome in China is estimated to be between 0.3% and 0.7%, with an increasing trend indicating a significant unmet clinical need [2] - Taitasip is a novel dual-target fusion protein developed by the company that simultaneously inhibits the overexpression of BLyS and APRIL, effectively preventing abnormal differentiation and maturation of B cells [2] Group 3: Regulatory and Clinical Recognition - Taitasip has received multiple authoritative guideline recommendations in China, including the "Clinical Practice Guidelines for Sjögren's Syndrome" and the "Expert Consensus on B-cell Targeted Therapy for Rheumatic and Immune Diseases" [2] - Internationally, Taitasip has been granted Fast Track designation by the U.S. FDA for its indication in Sjögren's syndrome and has been approved to conduct global multi-center Phase III clinical trials [2]

Core Viewpoint - Modern Dental Group (03600.HK) anticipates revenue growth for the first half of 2025, driven by natural growth and the acquisition of Hexa Ceram, with significant increases in EBITDA and net profit expected [1][2] Group 1: Financial Projections - The expected revenue for the first half of 2025 is between HKD 17.75 billion and HKD 18.5 billion, representing an increase of approximately 4.3% to 8.7% compared to the first half of 2024 [1] - The projected EBITDA for the first half of 2025 is between HKD 4.3 billion and HKD 4.7 billion, indicating an increase of approximately 14.5% to 25.1% from the first half of 2024 [1] - The anticipated net profit for the first half of 2025 is between HKD 2.79 billion and HKD 2.95 billion, reflecting an increase of approximately 30.1% to 37.6% compared to the first half of 2024 [1] Group 2: Growth Drivers - Revenue growth is primarily attributed to the company's ongoing natural growth, particularly in Europe and Australia, and is accelerated by the acquisition of Hexa Ceram, Thailand's largest dental laboratory [2] - The increase in EBITDA and net profit is driven by several factors, including a higher proportion of digital solution cases leading to improved operational efficiency [2] - Favorable currency fluctuations, particularly the appreciation of the Euro and Australian Dollar against the Renminbi and Hong Kong Dollar, have also contributed to the financial improvements [2]

（於開曼群島註冊成立的有限公司） （股份代號：3600） 正面盈利預告及內幕消息 本公告乃由現代牙科集團有限公司（「本公司」，連同其附屬公司統稱「本集團」）根據 香港聯合交易所有限公司證券上市規則（「上市規則」）第13.09條及香港法例第571章 證券及期貨條例（「證券及期貨條例」）第XIVA部項下的內幕消息條文（定義見上市規 則）作出。 本公司董事會（「董事會」）謹此知會本公司股東及有意投資者，基於對本集團最近可 得且未經本集團核數師及╱或審核委員會審核或審閱的截至 2025年6月30日止六 個月（「2025年上半年」）未經審核綜合管理賬目（「管理賬目」）的初步評估，本集團預 期： – 1 – (i) 2025年上半年的收益將介乎17億7千5百萬港元至18億5千萬港元，較截至 2024年6月30日止六個月（「2024年上半年」）的收益約17億1百8十萬港元，增 加約4.3%至8.7%； (ii) 2025年上半年的未計利息、稅項、折舊及攤銷前盈利（「EBITDA」）將介乎4億 3千萬港元至4億7千萬港元，較2024年上半年的EBITDA約3億7千5百6十萬 港元，增加約14.5%至25.1%；及 (iii) ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 現代牙科集團有限公司 (於開曼群島註冊成立的有限公司) 呈交日期: 2025年8月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 03600 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 3,000,000,000 | USD | | 0.01 | USD | | 30,000,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 3,000,000,000 | USD | | 0.01 | USD | | ...

Core Viewpoint - On July 28, 10 Hong Kong-listed companies conducted share buybacks, totaling 12.86 million shares and an amount of 10.74 million HKD [1][2] Group 1: Buyback Details - China Eastern Airlines repurchased 2.5 million shares for 7.50 million HKD, with a highest price of 3.030 HKD and a lowest price of 2.970 HKD, accumulating a total buyback amount of 613.45 million HKD for the year [1][2] - Carrot repurchased 160,000 shares for 816,000 HKD, with a highest price of 5.250 HKD and a lowest price of 5.080 HKD, accumulating a total buyback amount of 7.50 million HKD for the year [1][2] - Miniso repurchased 15,000 shares for 557,900 HKD, with a highest price of 37.200 HKD and a lowest price of 37.150 HKD, accumulating a total buyback amount of 313.34 million HKD for the year [1][2] Group 2: Buyback Rankings - The highest buyback amount on July 28 was from China Eastern Airlines at 7.50 million HKD, followed by Carrot at 816,000 HKD, and Miniso among others [1][2] - In terms of buyback quantity, Ying Group had the highest with 9.20 million shares, followed by China Eastern Airlines with 2.5 million shares and Maple Leaf Education with 428,000 shares [1][2]

Summary of Key Points Core Viewpoint - Several companies, including China Eastern Airlines and Miniso, conducted share buybacks on July 28, 2025, with China Eastern Airlines having the largest buyback amount of 749.83 million yuan for 2.5 million shares [1]. Group 1: Buyback Details - China Eastern Airlines (00670) repurchased 2.5 million shares for 749.83 million yuan, with a total annual buyback of 109 million shares, representing 2.106% of its total share capital [2]. - Carrot (N24025) repurchased 160,000 shares for 816,000 yuan, with a total annual buyback of 823,500 shares, accounting for 1.480% of its total share capital [2]. - Miniso (09896) repurchased 15,000 shares for 557,900 yuan, with a total annual buyback of 3.2419 million shares, representing 0.261% of its total share capital [2]. - Ying Group (00397) repurchased 9.2 million shares for 487,600 yuan, with a total annual buyback of 89.8 million shares, accounting for 3.780% of its total share capital [2]. - Modern Dental (03600) repurchased 100,000 shares for 424,600 yuan, with a total annual buyback of 4.1 million shares, representing 0.437% of its total share capital [2]. - Gacos (B) (01167) repurchased 47,400 shares for 354,500 yuan, with a total annual buyback of 110,400 shares, accounting for 0.014% of its total share capital [2]. - Lihong Inspection (01586) repurchased 76,000 shares for 235,600 yuan, with a total annual buyback of 1.484 million shares, representing 2.507% of its total share capital [2]. - Maple Leaf Education (01317) repurchased 428,000 shares for 158,400 yuan, with a total annual buyback of 42.554 million shares, accounting for 1.432% of its total share capital [2]. - Wanka Yilian (01762) repurchased 200,000 shares for 146,000 yuan, with a total annual buyback of 17.814 million shares, representing 1.006% of its total share capital [2]. - Hong Kong Food Investment (00060) repurchased 130,000 shares for 60,200 yuan, with a total annual buyback of 3.932 million shares, accounting for 1.515% of its total share capital [2].

表格類別： 股票 狀態： 新提交 FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 公司名稱： 現代牙科集團有限公司 (於開曼群島註冊成立的有限公司) 呈交日期： 2025年7月28日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 03600 | 說明 | 股份回購 | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | ...

Group 1 - The article reports on share buybacks conducted by various companies on July 25, 2025, with Yum China (09987) having the largest buyback amount of 6.2679 million yuan for 16,700 shares [1][2] - The total number of shares repurchased by Yum China in the year reached 3.2541 million, accounting for 0.870% of its total share capital [2] - Other notable companies involved in buybacks include Huajian Medical (01931) with 1.414 million shares repurchased for 5.0763 million yuan, and Mengniu Dairy (02319) with 200,000 shares for 3.4333 million yuan [2] Group 2 - The buyback activities reflect a strategic move by companies to enhance shareholder value and signal confidence in their financial health [1] - The buyback amounts and share counts for other companies include Xinyi International (00732) with 2.644 million shares for 3.2257 million yuan, and Beike-W (02423) with 462,600 shares for 3 million yuan [2] - The data indicates a diverse range of companies participating in buybacks, suggesting a broader trend in the market towards returning capital to shareholders [1][2]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 現代牙科集團有限公司 (於開曼群島註冊成立的有限公司) 呈交日期： 2025年7月25日 | 13). | 購回股份擬註銷但尚未註銷 | 100,000 | % | HKD | 4.2552 | | --- | --- | --- | --- | --- | --- | | | 變動日期 2025年6月17日 | | | | | | 14). | 購回股份擬註銷但尚未註銷 | 100,000 | % | HKD | 4.2361 | | | 變動日期 2025年6月18日 | | | | | | 15). | 購回股份擬註銷但尚未註銷 | 100,000 | % | HKD | 4.1195 | | | 變動日期 2025年6月19日 | | | | | | 16). | 購回股份擬註銷但尚未註銷 | 100,000 | % | HKD | 4.0935 | | | 變動日期 2025年6月20日 | | | | | | 17). | 購回股份擬註銷但尚未註 ...

Group 1 - On July 24, 17 Hong Kong-listed companies conducted share buybacks, totaling 17.15 million shares and an amount of 16.89 million HKD [1][2] - China Eastern Airlines repurchased 1.5 million shares for 4.44 million HKD, with a highest price of 2.980 HKD and a lowest price of 2.920 HKD, accumulating a total buyback amount of 606 million HKD for the year [1][2] - Mengniu Dairy repurchased 200,000 shares for 3.45 million HKD, with a highest price of 17.300 HKD and a lowest price of 17.240 HKD, accumulating a total buyback amount of 242 million HKD for the year [1][2] Group 2 - IGG repurchased 560,000 shares for 2.40 million HKD, with a highest price of 4.310 HKD and a lowest price of 4.260 HKD, accumulating a total buyback amount of 56.65 million HKD for the year [1][2] - The highest buyback amount on July 24 was from China Eastern Airlines at 4.44 million HKD, followed by Mengniu Dairy at 3.45 million HKD [1][2] - The largest number of shares repurchased on July 24 was by Ying Group, with a buyback of 5.5 million shares, followed by China Electric Power and Shoujia Technology [1][2]